Editorial Board Members’ Collection Series—Diagnosis and Management of Viral Hepatitis

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Diagnostic Microbiology and Infectious Disease".

Deadline for manuscript submissions: closed (28 September 2023) | Viewed by 1995

Special Issue Editors


E-Mail Website
Guest Editor
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Interests: molecular epidemiology; chronic hepatitis C and B; hepatocellular carcinoma

E-Mail Website
Guest Editor
LAPI, Department of Medicine and Diagnostic Support, School of Medicine, Federal University of Bahia, Augusto Viana, SN, Salvador, BA, Brazil
Interests: HIV; HTLV; viral hepatitis; co-infections; arboviruses; emergent viruses
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

We are pleased to announce this Collection titled, "Editorial Board Members' Collection Series - Diagnosis and Management of Viral Hepatitis". This issue will be a collection of papers from researchers invited by the Editorial Board Members. The aim is to provide a venue for networking and communication between Diagnostics and scholars in the field of Viral Hepatitis and Diagnosis and Management. All papers will be published as fully open access after peer review.

Prof. Dr. Chia-Yen Dai
Prof. Dr. Carlos Brites
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1837 KiB  
Article
Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy
by Chun-Hsien Chen, Chien-Heng Shen, Kuo-Liang Wei, Huang-Wei Xu, Wei-Ming Chen, Kao-Chi Chang, Yu-Ting Huang, Yung-Yu Hsieh, Sheng-Nan Lu, Chao-Hung Hung and Te-Sheng Chang
Diagnostics 2023, 13(3), 473; https://doi.org/10.3390/diagnostics13030473 - 27 Jan 2023
Cited by 1 | Viewed by 1463
Abstract
The findings regarding changes in renal function in patients with hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs) are controversial. This study attempted to identify the factors associated with the large decline in renal function following DAA treatment. This retrospective cohort [...] Read more.
The findings regarding changes in renal function in patients with hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs) are controversial. This study attempted to identify the factors associated with the large decline in renal function following DAA treatment. This retrospective cohort study included patients treated with DAAs at Chiayi and Yunlin Chang Gung Hospitals, Taiwan, from 1 January 2017 to 31 October 2020. Estimated glomerular filtration rate (eGFR) data were collected within 90 days prior to DAA therapy and 2 years after the confirmation of a sustained virologic response (SVR). We performed multiple logistic regression to evaluate the clinical or laboratory parameters associated with a large eGFR decline (≥10%). Among the enrolled 606 patients, the mean eGFR at the baseline and endpoint were 84.11 ± 24.38 and 78.88 ± 26.30 mL/min/1.73 m2, respectively (p < 0.001). The factors associated with a large eGFR decline 2 years after the SVR included hypertension (OR: 1.481; 95% CI: 1.010–2.173, p = 0.044) and a higher baseline eGFR (OR: 1.016; 95% CI: 1.007–1.024, p < 0.001). A higher albumin level reduced the risk of a large eGFR decline (OR: 0.546; 95% CI: 0.342–0.872, p = 0.011). In the patients with HCV treated with DAAs, a larger renal function decline was more commonly observed in those with hypertension, a lower (but within normal range) albumin level, and a higher baseline eGFR, while DAA treatment had no effect. The clinical significance of these findings has to be further defined. Although some risk factors associated with chronic kidney disease may be alleviated after DAA treatment, the regular control and follow-up of risk factors and renal function are still recommended in at-risk patients after HCV eradication. Full article
Show Figures

Figure 1

Back to TopTop